Loading…
Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Among US Female Patients with Recurrent Versus Non-Recurrent uUTI
To assess the relative likelihood of antimicrobial resistance (AMR) and multi-drug resistance (MDR) among E. coli isolates from outpatients with recurrent versus non-recurrent uncomplicated urinary tract infection (uUTI). In this retrospective observational US cohort study, female outpatients (≥12 y...
Saved in:
Published in: | Urology (Ridgewood, N.J.) N.J.), 2024-08, Vol.190, p.1-10 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c243t-fc6568ba457cc17cae19443de63aaee05e889174df86f93e0283da5942f7fc813 |
container_end_page | 10 |
container_issue | |
container_start_page | 1 |
container_title | Urology (Ridgewood, N.J.) |
container_volume | 190 |
creator | Fromer, Debra L. Cheng, Wendy Y. Gao, Chi Mahendran, Malena Hilts, Annalise Duh, Mei Sheng Joshi, Ashish V. Mulgirigama, Aruni Mitrani-Gold, Fanny S. |
description | To assess the relative likelihood of antimicrobial resistance (AMR) and multi-drug resistance (MDR) among E. coli isolates from outpatients with recurrent versus non-recurrent uncomplicated urinary tract infection (uUTI).
In this retrospective observational US cohort study, female outpatients (≥12 years) with uUTI, positive E. coli culture, and treated with ≥1 oral antibiotic within ±5 days of diagnosis were grouped into recurrent and non-recurrent uUTI cohorts per their UTI history (past 12 months). AMR to specific drug classes was evaluated at index. Univariable and multivariable logistic regression models estimated the likelihood of not-susceptible E. coli isolates (AMR/MDR) among patients with recurrent uUTI versus non-recurrent uUTI.
Recurrent (N = 12,234) and non-recurrent (N = 68,033) uUTI cohorts had similar distributions (race, ethnicity, region). Patients with recurrent uUTI had a higher prevalence of E. coli resistance to trimethoprim-sulfamethoxazole (21.8% vs 18.7%) and fluoroquinolones (14.2% vs 8.6%), and more isolates were extended-spectrum β-lactamase-producing (5.9% vs 4.1%) compared to non-recurrent uUTI patients. Patients with recurrent uUTI had a higher likelihood (odds ratio [95% confidence interval]) of any AMR (1.28 [1.22-1.34]), single drug-class resistance (1.18 [1.12-1.24]), and resistance to 2 (1.53 [1.41-1.67]) or ≥3 drug classes (1.70 [1.48-1.96]) (all P |
doi_str_mv | 10.1016/j.urology.2024.02.047 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2956159606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S009042952400150X</els_id><sourcerecordid>2956159606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-fc6568ba457cc17cae19443de63aaee05e889174df86f93e0283da5942f7fc813</originalsourceid><addsrcrecordid>eNqFUcFu1DAUtFARXQqfQOVjLwm2YzvxqVpVLay0AgRdrpbXeWm9deLWdkC98-G42i0ce3p6TzPzNDMIfaCkpoTKj7t6jsGHm8eaEcZrwmrC21doQQVrK6WUOEILQhSpOFPiGL1NaUcIkVK2b9Bx03HZso4v0J-1uwPvbkPocRjwcspudDaGrTMef4fkUjaTBewmvIluMvERX9bYBu_wKgVvMiS8HMN0gzc_8BWMxgP-ZrKDKSf82-XbImLnGMuOf0JMc8JfwlT9P86b69U79HowPsH7wzxBm6vL64vP1frrp9XFcl1ZxptcDVYK2W0NF621tLUGqOK86UE2xgAQAV2naMv7oZODaoCwrumNUJwN7WA72pygs73ufQwPM6SsR5cseG8mCHPSJSlJhZJEFqjYQ0sWKUUY9H10Y7GvKdFPBeidPhSgnwrQhOlSQOGdHl7M2xH6f6znxAvgfA-AYvSXg6iTLWlZ6F0Em3Uf3Asv_gKsRZuo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956159606</pqid></control><display><type>article</type><title>Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Among US Female Patients with Recurrent Versus Non-Recurrent uUTI</title><source>Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list)</source><creator>Fromer, Debra L. ; Cheng, Wendy Y. ; Gao, Chi ; Mahendran, Malena ; Hilts, Annalise ; Duh, Mei Sheng ; Joshi, Ashish V. ; Mulgirigama, Aruni ; Mitrani-Gold, Fanny S.</creator><creatorcontrib>Fromer, Debra L. ; Cheng, Wendy Y. ; Gao, Chi ; Mahendran, Malena ; Hilts, Annalise ; Duh, Mei Sheng ; Joshi, Ashish V. ; Mulgirigama, Aruni ; Mitrani-Gold, Fanny S.</creatorcontrib><description>To assess the relative likelihood of antimicrobial resistance (AMR) and multi-drug resistance (MDR) among E. coli isolates from outpatients with recurrent versus non-recurrent uncomplicated urinary tract infection (uUTI).
In this retrospective observational US cohort study, female outpatients (≥12 years) with uUTI, positive E. coli culture, and treated with ≥1 oral antibiotic within ±5 days of diagnosis were grouped into recurrent and non-recurrent uUTI cohorts per their UTI history (past 12 months). AMR to specific drug classes was evaluated at index. Univariable and multivariable logistic regression models estimated the likelihood of not-susceptible E. coli isolates (AMR/MDR) among patients with recurrent uUTI versus non-recurrent uUTI.
Recurrent (N = 12,234) and non-recurrent (N = 68,033) uUTI cohorts had similar distributions (race, ethnicity, region). Patients with recurrent uUTI had a higher prevalence of E. coli resistance to trimethoprim-sulfamethoxazole (21.8% vs 18.7%) and fluoroquinolones (14.2% vs 8.6%), and more isolates were extended-spectrum β-lactamase-producing (5.9% vs 4.1%) compared to non-recurrent uUTI patients. Patients with recurrent uUTI had a higher likelihood (odds ratio [95% confidence interval]) of any AMR (1.28 [1.22-1.34]), single drug-class resistance (1.18 [1.12-1.24]), and resistance to 2 (1.53 [1.41-1.67]) or ≥3 drug classes (1.70 [1.48-1.96]) (all P <.001).
This study delineated the likelihood of AMR and MDR among E. coli isolates from patients with recurrent versus non-recurrent uUTI. While some treatment guidelines support empiric therapy in recurrent uUTI, the increased likelihood of resistance among these patients suggests that culture and susceptibility testing should be undertaken to inform recurrent uUTI treatment.</description><identifier>ISSN: 0090-4295</identifier><identifier>ISSN: 1527-9995</identifier><identifier>EISSN: 1527-9995</identifier><identifier>DOI: 10.1016/j.urology.2024.02.047</identifier><identifier>PMID: 38467284</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Cohort Studies ; Drug Resistance, Bacterial ; Drug Resistance, Multiple, Bacterial ; Escherichia coli - drug effects ; Escherichia coli - isolation & purification ; Escherichia coli Infections - drug therapy ; Escherichia coli Infections - epidemiology ; Escherichia coli Infections - microbiology ; Female ; Humans ; Microbial Sensitivity Tests ; Middle Aged ; Recurrence ; Retrospective Studies ; United States - epidemiology ; Urinary Tract Infections - drug therapy ; Urinary Tract Infections - epidemiology ; Urinary Tract Infections - microbiology ; Young Adult</subject><ispartof>Urology (Ridgewood, N.J.), 2024-08, Vol.190, p.1-10</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-fc6568ba457cc17cae19443de63aaee05e889174df86f93e0283da5942f7fc813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38467284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fromer, Debra L.</creatorcontrib><creatorcontrib>Cheng, Wendy Y.</creatorcontrib><creatorcontrib>Gao, Chi</creatorcontrib><creatorcontrib>Mahendran, Malena</creatorcontrib><creatorcontrib>Hilts, Annalise</creatorcontrib><creatorcontrib>Duh, Mei Sheng</creatorcontrib><creatorcontrib>Joshi, Ashish V.</creatorcontrib><creatorcontrib>Mulgirigama, Aruni</creatorcontrib><creatorcontrib>Mitrani-Gold, Fanny S.</creatorcontrib><title>Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Among US Female Patients with Recurrent Versus Non-Recurrent uUTI</title><title>Urology (Ridgewood, N.J.)</title><addtitle>Urology</addtitle><description>To assess the relative likelihood of antimicrobial resistance (AMR) and multi-drug resistance (MDR) among E. coli isolates from outpatients with recurrent versus non-recurrent uncomplicated urinary tract infection (uUTI).
In this retrospective observational US cohort study, female outpatients (≥12 years) with uUTI, positive E. coli culture, and treated with ≥1 oral antibiotic within ±5 days of diagnosis were grouped into recurrent and non-recurrent uUTI cohorts per their UTI history (past 12 months). AMR to specific drug classes was evaluated at index. Univariable and multivariable logistic regression models estimated the likelihood of not-susceptible E. coli isolates (AMR/MDR) among patients with recurrent uUTI versus non-recurrent uUTI.
Recurrent (N = 12,234) and non-recurrent (N = 68,033) uUTI cohorts had similar distributions (race, ethnicity, region). Patients with recurrent uUTI had a higher prevalence of E. coli resistance to trimethoprim-sulfamethoxazole (21.8% vs 18.7%) and fluoroquinolones (14.2% vs 8.6%), and more isolates were extended-spectrum β-lactamase-producing (5.9% vs 4.1%) compared to non-recurrent uUTI patients. Patients with recurrent uUTI had a higher likelihood (odds ratio [95% confidence interval]) of any AMR (1.28 [1.22-1.34]), single drug-class resistance (1.18 [1.12-1.24]), and resistance to 2 (1.53 [1.41-1.67]) or ≥3 drug classes (1.70 [1.48-1.96]) (all P <.001).
This study delineated the likelihood of AMR and MDR among E. coli isolates from patients with recurrent versus non-recurrent uUTI. While some treatment guidelines support empiric therapy in recurrent uUTI, the increased likelihood of resistance among these patients suggests that culture and susceptibility testing should be undertaken to inform recurrent uUTI treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Cohort Studies</subject><subject>Drug Resistance, Bacterial</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - isolation & purification</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Escherichia coli Infections - epidemiology</subject><subject>Escherichia coli Infections - microbiology</subject><subject>Female</subject><subject>Humans</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>United States - epidemiology</subject><subject>Urinary Tract Infections - drug therapy</subject><subject>Urinary Tract Infections - epidemiology</subject><subject>Urinary Tract Infections - microbiology</subject><subject>Young Adult</subject><issn>0090-4295</issn><issn>1527-9995</issn><issn>1527-9995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFUcFu1DAUtFARXQqfQOVjLwm2YzvxqVpVLay0AgRdrpbXeWm9deLWdkC98-G42i0ce3p6TzPzNDMIfaCkpoTKj7t6jsGHm8eaEcZrwmrC21doQQVrK6WUOEILQhSpOFPiGL1NaUcIkVK2b9Bx03HZso4v0J-1uwPvbkPocRjwcspudDaGrTMef4fkUjaTBewmvIluMvERX9bYBu_wKgVvMiS8HMN0gzc_8BWMxgP-ZrKDKSf82-XbImLnGMuOf0JMc8JfwlT9P86b69U79HowPsH7wzxBm6vL64vP1frrp9XFcl1ZxptcDVYK2W0NF621tLUGqOK86UE2xgAQAV2naMv7oZODaoCwrumNUJwN7WA72pygs73ufQwPM6SsR5cseG8mCHPSJSlJhZJEFqjYQ0sWKUUY9H10Y7GvKdFPBeidPhSgnwrQhOlSQOGdHl7M2xH6f6znxAvgfA-AYvSXg6iTLWlZ6F0Em3Uf3Asv_gKsRZuo</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Fromer, Debra L.</creator><creator>Cheng, Wendy Y.</creator><creator>Gao, Chi</creator><creator>Mahendran, Malena</creator><creator>Hilts, Annalise</creator><creator>Duh, Mei Sheng</creator><creator>Joshi, Ashish V.</creator><creator>Mulgirigama, Aruni</creator><creator>Mitrani-Gold, Fanny S.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202408</creationdate><title>Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Among US Female Patients with Recurrent Versus Non-Recurrent uUTI</title><author>Fromer, Debra L. ; Cheng, Wendy Y. ; Gao, Chi ; Mahendran, Malena ; Hilts, Annalise ; Duh, Mei Sheng ; Joshi, Ashish V. ; Mulgirigama, Aruni ; Mitrani-Gold, Fanny S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-fc6568ba457cc17cae19443de63aaee05e889174df86f93e0283da5942f7fc813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Cohort Studies</topic><topic>Drug Resistance, Bacterial</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - isolation & purification</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Escherichia coli Infections - epidemiology</topic><topic>Escherichia coli Infections - microbiology</topic><topic>Female</topic><topic>Humans</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>United States - epidemiology</topic><topic>Urinary Tract Infections - drug therapy</topic><topic>Urinary Tract Infections - epidemiology</topic><topic>Urinary Tract Infections - microbiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fromer, Debra L.</creatorcontrib><creatorcontrib>Cheng, Wendy Y.</creatorcontrib><creatorcontrib>Gao, Chi</creatorcontrib><creatorcontrib>Mahendran, Malena</creatorcontrib><creatorcontrib>Hilts, Annalise</creatorcontrib><creatorcontrib>Duh, Mei Sheng</creatorcontrib><creatorcontrib>Joshi, Ashish V.</creatorcontrib><creatorcontrib>Mulgirigama, Aruni</creatorcontrib><creatorcontrib>Mitrani-Gold, Fanny S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urology (Ridgewood, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fromer, Debra L.</au><au>Cheng, Wendy Y.</au><au>Gao, Chi</au><au>Mahendran, Malena</au><au>Hilts, Annalise</au><au>Duh, Mei Sheng</au><au>Joshi, Ashish V.</au><au>Mulgirigama, Aruni</au><au>Mitrani-Gold, Fanny S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Among US Female Patients with Recurrent Versus Non-Recurrent uUTI</atitle><jtitle>Urology (Ridgewood, N.J.)</jtitle><addtitle>Urology</addtitle><date>2024-08</date><risdate>2024</risdate><volume>190</volume><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0090-4295</issn><issn>1527-9995</issn><eissn>1527-9995</eissn><abstract>To assess the relative likelihood of antimicrobial resistance (AMR) and multi-drug resistance (MDR) among E. coli isolates from outpatients with recurrent versus non-recurrent uncomplicated urinary tract infection (uUTI).
In this retrospective observational US cohort study, female outpatients (≥12 years) with uUTI, positive E. coli culture, and treated with ≥1 oral antibiotic within ±5 days of diagnosis were grouped into recurrent and non-recurrent uUTI cohorts per their UTI history (past 12 months). AMR to specific drug classes was evaluated at index. Univariable and multivariable logistic regression models estimated the likelihood of not-susceptible E. coli isolates (AMR/MDR) among patients with recurrent uUTI versus non-recurrent uUTI.
Recurrent (N = 12,234) and non-recurrent (N = 68,033) uUTI cohorts had similar distributions (race, ethnicity, region). Patients with recurrent uUTI had a higher prevalence of E. coli resistance to trimethoprim-sulfamethoxazole (21.8% vs 18.7%) and fluoroquinolones (14.2% vs 8.6%), and more isolates were extended-spectrum β-lactamase-producing (5.9% vs 4.1%) compared to non-recurrent uUTI patients. Patients with recurrent uUTI had a higher likelihood (odds ratio [95% confidence interval]) of any AMR (1.28 [1.22-1.34]), single drug-class resistance (1.18 [1.12-1.24]), and resistance to 2 (1.53 [1.41-1.67]) or ≥3 drug classes (1.70 [1.48-1.96]) (all P <.001).
This study delineated the likelihood of AMR and MDR among E. coli isolates from patients with recurrent versus non-recurrent uUTI. While some treatment guidelines support empiric therapy in recurrent uUTI, the increased likelihood of resistance among these patients suggests that culture and susceptibility testing should be undertaken to inform recurrent uUTI treatment.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38467284</pmid><doi>10.1016/j.urology.2024.02.047</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-4295 |
ispartof | Urology (Ridgewood, N.J.), 2024-08, Vol.190, p.1-10 |
issn | 0090-4295 1527-9995 1527-9995 |
language | eng |
recordid | cdi_proquest_miscellaneous_2956159606 |
source | Elsevier:Jisc Collections:Elsevier Read and Publish Agreement 2022-2024:Freedom Collection (Reading list) |
subjects | Adolescent Adult Aged Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Cohort Studies Drug Resistance, Bacterial Drug Resistance, Multiple, Bacterial Escherichia coli - drug effects Escherichia coli - isolation & purification Escherichia coli Infections - drug therapy Escherichia coli Infections - epidemiology Escherichia coli Infections - microbiology Female Humans Microbial Sensitivity Tests Middle Aged Recurrence Retrospective Studies United States - epidemiology Urinary Tract Infections - drug therapy Urinary Tract Infections - epidemiology Urinary Tract Infections - microbiology Young Adult |
title | Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Among US Female Patients with Recurrent Versus Non-Recurrent uUTI |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Likelihood%20of%20Antimicrobial%20Resistance%20in%20Urinary%20E.%20coli%20Isolates%20Among%20US%20Female%20Patients%20with%20Recurrent%20Versus%20Non-Recurrent%20uUTI&rft.jtitle=Urology%20(Ridgewood,%20N.J.)&rft.au=Fromer,%20Debra%20L.&rft.date=2024-08&rft.volume=190&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0090-4295&rft.eissn=1527-9995&rft_id=info:doi/10.1016/j.urology.2024.02.047&rft_dat=%3Cproquest_cross%3E2956159606%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c243t-fc6568ba457cc17cae19443de63aaee05e889174df86f93e0283da5942f7fc813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956159606&rft_id=info:pmid/38467284&rfr_iscdi=true |